Cancer immunotherapy - Immune checkpoint blockade and associated endocrinopathies Journal Article
| Authors: | Byun, D. J.; Wolchok, J. D.; Rosenberg, L. M.; Girotra, M. |
| Article Title: | Cancer immunotherapy - Immune checkpoint blockade and associated endocrinopathies |
| Abstract: | Advances in cancer therapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) are two co-inhibitory receptors that are expressed on activated T cells against which therapeutic blocking antibodies have reached routine clinical use. Immune checkpoint blockade can induce inflammatory adverse effects, termed immune-related adverse events (IRAEs), which resemble autoimmune disease. In this Review, we describe the current data regarding immune-related endocrinopathies, including hypophysitis, thyroid dysfunction and diabetes mellitus. We discuss the clinical management of these endocrinopathies within the context of our current understanding of the mechanisms of IRAEs. |
| Keywords: | clinical presentation; phase-ii trial; metastatic melanoma; cell lung-cancer; hypophysitis; adverse events; autoimmune; advanced melanoma; t-lymphocyte antigen-4; long-term safety; ipilimumab-induced hypophysitis; thyroid-disease |
| Journal Title: | Nature Reviews Endocrinology |
| Volume: | 13 |
| Issue: | 4 |
| ISSN: | 1759-5029 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2017-04-01 |
| Start Page: | 195 |
| End Page: | 207 |
| Language: | English |
| ACCESSION: | WOS:000396002800003 |
| DOI: | 10.1038/nrendo.2016.205 |
| PROVIDER: | wos |
| PUBMED: | 28106152 |
| PMCID: | PMC5629093 |
| Notes: | Review -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work